Heparin-lnduced thrombocytopenia in France, 1980-1998

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2 SUPPL. 1, 1999, Pages 9-15

  Nguyen, Philippe ^a   De Maistre, Emmanuel ^b   Cornillet Lefebvre, Pascale ^b   Regnault, Veronique ^b   Lecompte, Thomas ^b  

^a SERVICE DE DERMATOLOGIE   (France)

^b NONE

Author keywords

Argatroban; Danaparoid; Heparin induced thrombocytopenia (HIT); Hirudin; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ARGATROBAN; DANAPAROID; DEXTRAN; DIPYRIDAMOLE; HEPARIN; ILOPROST; IMMUNOGLOBULIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; ANTICOAGULANT AGENT; CHONDROITIN SULFATE; DERMATAN SULFATE; DRUG DERIVATIVE; HEPARAN SULFATE; HIRUDIN DERIVATIVE; RECOMBINANT PROTEIN;

ANTICOAGULATION; CONFERENCE PAPER; DRUG CHOICE; DRUG INDICATION; DRUG INDUCED DISEASE; FRANCE; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RELIABILITY; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY;

ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRANCE; HEPARIN; HEPARITIN SULFATE; HIRUDIN THERAPY; HIRUDINS; HUMANS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0032923962     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Aiach M, Boneu B, Potron G, Samama M, on behalf of Groupe d'Etude sur l'Hémostase et la Thrombose (GEHT) de la Société Française d'Hématologie. Utilisation des héparines en pratique médicale courante. Sang Thrombose Vaisseaux 1996;8:5-13
2. Nguyen P, Lecompte T, and Groupe d'Etude sur l'Hémostase et la Thrombose (GEHT) de la Société Française d'Hématologie. Heparin-induced thrombocytopenia: A survey of tests employed and attitudes in haematology laboratories. Nouv Rev Fr Hematol 1994;36:353-357
3. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemostas 1993;69:344-350
4. Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: Confirmation of diagnosis with in vitro methods. Blood 1975;45:395-401
5. Anderson CL, Chacko GW, Osborne JM, Brandt JT. The Fc receptor for immunoglobulin G (FcγRII) on human platelets. Sang Thrombose Vaisseaux 1995;21:1-9
6. Bachelot C, Saffroy R, Gandrille S, Aiach M, Rendu F. Role of FcγRII gene polymorphism in human platelet activation by monoclonal antibodies. Thromb Haemostas 1995;74:1557-1563
7. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet FcγRIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemostas 1995;74:1564-1572
8. Burgess JK, Lindeman R, Chesterman CN, Chong BH. Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 1995;91:761-766
9. Morel MC, Lecompte T, Champeix P, et al. A monoclonal murine antibody, PL2-49, which is a platelet activator. Br J Haematol 1989;71:57-63
10. Lecompte T, Stieltjes N, Shao-Kai L, et al. Heparin-and streptokinase-dependent platelet-activating immunoglohulin G: Mechanism and diagnosis. Semin Thromb Hemostas 1995;21:95-105
11. Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: Studies with a new low-molecular-weight heparinoid, Org 10172. Blood 1989;73:1592-1596
12. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 1993;70:554-561
13. Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemostas 1995;74:1384-1385
14. McCabe White M, Siders L, Jennings LK, White FL. The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia. Thromb Haemostas 1992;68:88(Letter)
15. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30
16. Pouplard C, Amiral J, Borg JY, et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997;99:273-280
17. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated to heparin induced thrombocytopenia. Thromb Haemostas 1992;68:95-96
18. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemostas 1994;71:247-251
19. Nguyen P, Droulle C, Potron G. Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin-induced thrombocytopenia. Thromb Haemostas 1995;74:804-805 (Letter)
20. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Coagulation Transfusion Med 1995;104:648-654
21. Petersen F, Flad HD, Brandt E. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. J Immunol 1994;152:2467-2478
22. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin 8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-416
23. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-1049
24. Nguyen P, Petitfrère E, Potron G. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. Thromb Res 1995; 78:33-42
25. Chignard M, Renesto P. Proteinases and cytokines in neutrophil and platelet interactions in vitro. Possible relevance to the adult respiratory distress syndrome. Ann NY Acad Sci 1994; 725:309-322
26. Pouplard C, May MA, Delahousse B, et al. Development of antibodies specific to PF4/heparin complexes in patients undergoing cardio-pulmonary bypass. Thromb Haemostas 1997;78; Suppl 448(Abst)
27. Trossaërt M, Gaillard A, Commin PL, et al. High frequency of anti-heparin/PF4 antibodies in cardiopulmonary bypass. Thromb Haemostas 1997;78(Suppl):449(Abst)
28. Amiral J, Peynaud-Debayle E, Wolf M, et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996;52:90-95
29. Amiral J, Wolf M, Fischer AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92: 954-959
30. Elalamy I, Potevin F, Lecrubier C, et al. A fatal low-molecular-weight heparin associated with thrombocytopenia after hip surgery: Possible usefulness of PF4-heparin ELISA test. Blood Coag Fibrinolysis 1996;7:665-671
31. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
32. Eichinger S, Kirle PA, Brenner B, et al. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991;337: 1425-1426(Letter)
33. Tardy B, Tardy-Poncet B, Zeni F, et al. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991;338: 1217(Letter)
34. Lecompte T, Luo SK, Stieltjes N, Lecrubier C, Samama MM. Thrombocytopenia associated with low molecular weight heparin. Lancet 1991;338:1217(Letter)
35. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194-2197
36. Tardy-Poncet B, Reynaud J, Tardy B, et al. Thrombopénie induite par l'héparine: Traitement par l'Org 10172. Tolérance et efficacité. Presse Med 1996;25:751-755
37. Doherty DC, Ortel TL, de Bruijn J, Greenberg CS, van Trigt PV. "Heparin-free" cardiopulmonary bypass: First reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990;73:562-565
38. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992;22:85-91
39. Schmidt OH, Lang W. Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin. N Engl J Med 1997;337:1389 (Letter)
40. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemostas 1993;70:286-288
41. Pötzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood Ecarin clotting time. Thromb Haemostas 1997;77:920-925
42. Addonizio VP, Fischer CA, Kappa JR, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 1987;102:796-807
43. Gruel Y, Lermusiaux P, Lang M, et al. Usefulness of iloprost in the management of heparin-associated thrombocytopenia and thrombosis. Thromb Haemostas 1989;62:49(Abst)
44. Greinacher A, Liebenhoff U, Kiefel V, Presek P, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: The effects of various intravenous IgG preparations on antibody mediated platelet activation: a possible new indication for high dose IV IgG. Thromb Haemostas 1994;71:641-645
45. Vergnes C, Laïs C, Macchi L, et al. Use of intravenous immunoglobulin (IVIgG) in the heparin-induced thrombocytopenia (HIT) with thromboembolic complications: Report of 5 cases. Thromb Haemostas 1997;78(Suppl);563(Abst)
46. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699